Executive Profiles

Natalie Douglas talks about her experience in the area of managed and expanded access and her new venture, RareiTi.

Leela Barham talks to Dr. Brian O’Rourke, outgoing President and Chief Executive Officer of the Canadian Agency for Drugs and Technologies in Health (CADTH), about his 11 in years in the role.

Led in part by its new head of the Americas business, Sebastian Guth, Bayer went all in in 2019 on expanding pursuits in science and discovery, striking deals with 11 digital health startups and upping investment in disease-detection programs and patient engagement and education.

AstraZeneca's Joris Silon outlines the company's efforts in CVRM (Cardiovascular, Renal and Metabolism) and the potential impact on type-2 diabetes and chronic kidney disease of SGLT2 inhibitors such as Forxiga.

Hari Pujar, chief technology officer of Spark Therapeutics, discusses the unique manufacturing and scale-up challenges involved with cell and gene therapy production.

Korn Ferry's Dr. Paul Pospisil talks to HBSHAA's Michael Wong about why biopharma employees should be excited about the industry's prospects.

Lundbeck executive Taj Bhardwaj talks about the differing mindsets necessary to lead local and global-level market access strategy in pharma-and how his current company is committed to stay in the fight to advance new treatments and break down stigmas in mental health.

Amy Mahery, last month appointed Global Head of Market Access and Pricing of the healthcare business of Merck KGaA, Darmstadt, Germany, discusses her key priorities and how she will draw on her multi-faceted industry experience to approach the challenges ahead.

Aiforia Technologies CEO Kaisa Helminen talks about the benefits of pharma embracing digital technologies, especially AI-assisted image analysis in the field of histopathology.

Pharm Exec chronicles the journey of gene therapy visionary R. Jude Samulski, whose work unraveling the mysteries of adeno-associated virus continues to fuel new hopes in transforming drugs for rare disease.

Sebastian Guth, President of Pharmaceuticals, Americas Region for Bayer, shares the company's long-term vision.

Michael Wong speaks to Dr. Marc Grodman about leading BioReference, his new role as CEO of Genosity, and the future of digital transformation.

Jennifer Buell, chief operating officer at Agenus, discusses the need for additional immunotherapies and combination strategies in cancer-building on learnings from the first wave of immune checkpoint inhibitors.

Tina Tianning Yu, Chief Executive Officer of Mevion Medical Systems, talks about engaging with China's pharma market and laying the foundations for success in 2020 and beyond.

French independent pharma Servier Group, led by president Olivier Laureau, is uniquely positioned to capitalize on new opportunities for expansion and stay true to its R&D and patient-focused mission.

Corey McCann, president and CEO of Pear Therapeutics, discusses how the prescription digital therapeutics space has evolved in a decade from disruptive concept to an exciting, growing market.

Pharm Exec speaks to Katya Svoboda, Taneesha Chawla, and Tanvi Ahuja about the growing practice of applying AI and machine learning in value-based and outcomes-based contracts.

Bernhardt Zeiher, Chief Medical Officer of Astellas discusses how the company transitioned from a traditional R&D approach to a platform approach, the need for innovation models to change in pharma, and the impact academia has on drug development.

Dr. Chris Cutie, chief medical officer of TARIS Bio, discusses his focus on creating new therapies for the often-misunderstood bladder disease population.

William Golden, founder, chairman and CEO of Noveome Biotherapeutics, talks about the potential of the company's lead product, ST266.

Dr. Steven Fox, CEO of Akelos Inc., discusses the challenges of developing new non-opioid medical products as the need intensifies as the crisis worsens.

In this Q&A, VP of Crisis Intelligence at Crisp discusses potential crisis points for the pharmaceutical industry.

Leela Barham talks to Sir David Haslam, the outgoing Chair of UK’s National Institute for Health and Care Excellence (NICE), about the highs and lows of his six-year tenure at the organization.

Pharm Exec speaks with Geoff MacKay, co-founder and CEO of AVROBIO, about the company’s mission to advance potentially curative lentiviral-based gene therapies, his career building businesses and innovation in regenerative medicine, and his most important quest to date-moving gene therapy into the mainstream.

Pharm Exec highlights a recent fireside chat between Veeva’s Matt Wallach and Jeffrey Marrazzo, CEO of Luxturna maker Spark Therapeutics.